Press Release Summary = NeuproŽ is available in the European market since March 2006 for the treatment of early stage idiopathic Parkinson\'s disease as monotherapy (i.e. without levodopa). The drug has already been launched by SCHWARZ PHARMA in Germany, the UK, Austria, Denmark, Ireland, Norway, Switzerland, Sweden, Greece and Spain.
Press Release Body = NeuproŽ is available in the European market since March 2006 for the treatment of early stage idiopathic Parkinson\'s disease as monotherapy (i.e. without levodopa). The drug has already been launched by SCHWARZ PHARMA in Germany, the UK, Austria, Denmark, Ireland, Norway, Switzerland, Sweden, Greece and Spain.
NeuproŽ, with the active ingredient rotigotine, is a non-ergoline dopamine receptor-agonist formulated as a transdermal delivery system, a patch. The patch is applied to the skin once a day and provides rotigotine continuously to the body for 24 hours. It, therefore, covers symptoms not only during the day, but also at night. Multinational clinical studies with patients in early and advanced stages of Parkinson\'s disease have shown efficacy and safety in Parkinson\'s disease patients and a potential for long term benefit. In more than 20 clinical trials, more than 2,000 patients with early or advanced Parkinson's disease have been treated with rotigotine transdermal patch.
For more: http://neupro.virtuale.org/neupro_and_health_canada.html
2012
